Skip to main content

Month: March 2022

Stitch Fix Announces New Employee Inducement Grants

SAN FRANCISCO, March 15, 2022 (GLOBE NEWSWIRE) — Stitch Fix, Inc. (NASDAQ:SFIX), the leading online personal styling service, today announced that effective March 10, 2022, the compensation committee of the company’s board of directors granted Sachin Dhawan, Chief Technology Officer, the option to purchase 612,170 shares of the company’s Class A common stock, at a per share exercise price of $11.31, and restricted stock units (“RSU”) to acquire 306,085 shares of the company’s Class A common stock. One fourth (25%) of the stock options will vest on June 24, 2022, 4.17% of the options will vest each month over the following 6 months, 2.78% of the options will vest each month over the following 12 months, and 1.385% of the options will vest each month over the remaining 12 months, subject to Mr. Dhawan’s continued service on each...

Continue reading

Sandy Spring Bancorp Announces Pricing of $200 Million Subordinated Debt Offering

OLNEY, Md., March 15, 2022 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (NASDAQ- SASR) (“Sandy Spring Bancorp” or the “Company”), the holding company for Sandy Spring Bank (the “Bank”), today announced that it has priced an underwritten public offering of $200 million aggregate principal amount of its fixed-to-floating rate subordinated notes due 2032 (the “Notes”). The Notes will initially bear a fixed interest rate of 3.875% per year. Commencing on March 30, 2027, the Notes will bear interest at a floating rate per annum equal to the benchmark rate (which is expected to be the three-month SOFR rate) plus a spread of 196.5 basis points, payable quarterly in arrears. The offering is expected to close on March 18, 2022, subject to the satisfaction of customary closing conditions. The Company plans to use the net proceeds from the...

Continue reading

Gold Standard Ventures Files Feasibility Study Technical Report on South Railroad Project

VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) — Gold Standard Ventures Corp. (NYSE AMERICAN: GSV) (TSX: GSV) (“Gold Standard” or the “Company”) is pleased to announce that the Company has filed a technical report, prepared in accordance with National Instrument 43-101, for its South Railroad Project located in Elko, Nevada. Gold Standard previously released the results of the Feasibility Study (see news release dated February 23, 2022) which demonstrate a robust project with low capital intensity, rapid payback, and peer leading returns. Key highlights contained in the technical report are presented below. The technical report is available on SEDAR under the Company’s profile at www.sedar.com and on Gold Standard’s website at www.goldstandardv.com. South Railroad Project Feasibility Study Highlights (all figures...

Continue reading

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults

Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who received an additional booster dose of Pfizer-BioNTech COVID-19 Vaccine compared to individuals who received only an initial boosterNEW YORK and MAINZ, GERMANY, March 15, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines. The submission is based on two real-world data sets from Israel analyzed at a time when the Omicron variant was...

Continue reading

Global Internet of People, Inc. to Hold Extraordinary General Meeting of Shareholders on April 1, 2022

BEIJING, March 15, 2022 (GLOBE NEWSWIRE) —  Global Internet of People, Inc. (“SDH” or the “Company”) (NASDAQ: SDH), an operator of a knowledge sharing and enterprise service platform via mobile application and through local centers in China, today announced that it has filed a proxy statement for an extraordinary general meeting (the “Meeting”) of holders of ordinary shares on March 15, 2022 and expects to hold the Meeting on April 1, 2022 at 9:30 a.m., Eastern Time (April 1, 2022, at 9:30 p.m., Beijing Time). To mitigate risks to the Company’s shareholders (the “Shareholders”), employees and other stakeholders, due to COVID-19, the Company will hold the Meeting in a virtual only format, which will be conducted via live audio webcast. Shareholders will be able to attend the Meeting and engage with the directors, management, and...

Continue reading

Global Internet of People, Inc. Announces Appointment of Independent Director

Beijing, China, March 15, 2022 (GLOBE NEWSWIRE) — Global Internet of People, Inc. (“SDH” or the “Company”) (NASDAQ: SDH), an operator of a knowledge sharing and enterprise service platform via mobile application and through local centers in China, today announced the appointment of Dr. Xiang (Roy) Luo as a member of its board of directors (the “Board”), effective March 11, 2022, to replace Mr. John G. Nossiff, who resigned from the Board for personal reasons. Mr. Haiping Hu, CEO and Chairman of SDH commented: “We thank Mr. John G. Nossiff for his service to the Board for the past year, and are honored to have Mr. Luo join our Board as an independent director. Mr. Luo is an accomplished professional with extensive experiences in carbon neutral and sustainable development strategies. We are confident that Mr. Luo will provide valuable...

Continue reading

Maxim Power Corp. Announces 2021 Fourth Quarter Financial and Operating Results, and Reports Significant Earnings with $156 million of Revenues, $79 million of Net Income and Record Adjusted EBITDA of $68 million in 2021

CALGARY, Alberta, March 15, 2022 (GLOBE NEWSWIRE) — Maxim Power Corp. (“MAXIM” or the “Corporation”) (TSX: MXG) announced today the release of financial and operating results for the fourth quarter ended December 31, 2021. The audited consolidated financial statements, accompanying notes and Management’s Discussion and Analysis (“MD&A”) will be available on SEDAR and on MAXIM’s website on March 15, 2022. All figures reported herein are Canadian dollars unless otherwise stated. FINANCIAL HIGHLIGHTS  Three Months EndedDecember 31, Twelve Months Ended December 31,($ in thousands except per share amounts) 2021 2020 2021 2020Revenue 37,418 17,282 156,014 46,726Net income 4,402 8,923 78,509 9,260Earnings per share – basic 0.09 0.18 1.57 0.19Earnings per share – diluted 0.08 0.18 1.28 0.18Adjusted...

Continue reading

Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights

– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway – – Expect to enroll first patient in Phase 1/2 trial of INZ-701 for ABCC6 Deficiency in the second quarter of 2022 – – Preliminary safety and biomarker data from Phase 1/2 trials in ENPP1 Deficiency and ABCC6 Deficiency on track for the first half of 2022 – BOSTON, March 15, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the full year ended December 31, 2021, and provided recent business highlights. “2021 was a transformational year for Inozyme, as we continued to progress our INZ-701 program and graduated to a clinical-stage company. We initiated our first clinical trial...

Continue reading

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

– Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 – $29.7 Million in Cash as of December 31, 2021 – CUPERTINO, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today reported financial results for the full year ended December 31, 2021 and summarized recent business highlights. “2021 was a year of significant progress that capped off with initiation of our pivotal Phase 3 and long-term safety trials in January evaluating brilaroxazine in schizophrenia. We are highly...

Continue reading

Northview Fund Announces 2021 Financial Results

Not for distribution to U.S. newswire services or for dissemination in the United States. CALGARY, Alberta, March 15, 2022 (GLOBE NEWSWIRE) — Northview Fund (“Northview” or the “Fund”, formerly known as Northview Canadian High Yield Residential Fund) (NHF.UN – TSX), today announced financial results for the three months and year ended December 31, 2021. The comparative information included for the period ended December 31, 2020 reflects results for the period from November 2, 2020, the date on which Northview began operations, to December 31, 2020. While comparative information is presented on a quarterly and annual basis, the operating periods in the period ended December 31, 2020 and the year ended December 31, 2021 cover different time frames and, as such, are not comparable. All amounts in this news release are in thousands...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.